Calibration and cross-validation of MCCB and CogState in schizophreniaCitation formats

  • External authors:
  • Eve Applegate
  • Richard Emsley
  • Panayiota G. Michalopoulou
  • Tracy Collier
  • Cristina Lopez-Lopez
  • S Kapur
  • Gahan Pandina

Standard

Calibration and cross-validation of MCCB and CogState in schizophrenia. / Lees, Jane; Applegate, Eve; Emsley, Richard; Lewis, Shon; Michalopoulou, Panayiota G.; Collier, Tracy; Lopez-Lopez, Cristina; Kapur, S; Pandina, Gahan; Drake, Richard.

In: Psychopharmacology, Vol. 232, No. 21-22, 29.05.2015, p. 3873-3882.

Research output: Contribution to journalArticle

Harvard

Lees, J, Applegate, E, Emsley, R, Lewis, S, Michalopoulou, PG, Collier, T, Lopez-Lopez, C, Kapur, S, Pandina, G & Drake, R 2015, 'Calibration and cross-validation of MCCB and CogState in schizophrenia', Psychopharmacology, vol. 232, no. 21-22, pp. 3873-3882. https://doi.org/10.1007/s00213-015-3960-8

APA

Lees, J., Applegate, E., Emsley, R., Lewis, S., Michalopoulou, P. G., Collier, T., ... Drake, R. (2015). Calibration and cross-validation of MCCB and CogState in schizophrenia. Psychopharmacology, 232(21-22), 3873-3882. https://doi.org/10.1007/s00213-015-3960-8

Vancouver

Lees J, Applegate E, Emsley R, Lewis S, Michalopoulou PG, Collier T et al. Calibration and cross-validation of MCCB and CogState in schizophrenia. Psychopharmacology. 2015 May 29;232(21-22):3873-3882. https://doi.org/10.1007/s00213-015-3960-8

Author

Lees, Jane ; Applegate, Eve ; Emsley, Richard ; Lewis, Shon ; Michalopoulou, Panayiota G. ; Collier, Tracy ; Lopez-Lopez, Cristina ; Kapur, S ; Pandina, Gahan ; Drake, Richard. / Calibration and cross-validation of MCCB and CogState in schizophrenia. In: Psychopharmacology. 2015 ; Vol. 232, No. 21-22. pp. 3873-3882.

Bibtex

@article{9e837f6b189a48c6a6bfd8a9673c90ec,
title = "Calibration and cross-validation of MCCB and CogState in schizophrenia",
abstract = "RATIONALE: Cognitive impairment associated with schizophrenia is a key predictor of functional outcomes. The FDA-accepted MATRICS Consensus Cognitive Battery (MCCB) is held to be the gold standard measure but there are concerns about its ease of administration, reliance on language causing problems with translation and possible practice effects. The CogState Schizophrenia Battery (SB) is suggested as a non-language-based alternative but there is no substantial, independent comparison.OBJECTIVES: The objective of this study was to assess the reliability and validity of these two assessment batteries.METHODS: One hundred forty-three participants with DSM-IV schizophrenia and schizoaffective disorder were recruited into three similar studies. Each study administered MCCB and SB tests on consecutive days (baseline 1 and 2) and follow-up 3-4 weeks later.RESULTS: Batteries' test-retest reliability was similar: SB composites correlated r = 0.66-0.78 between baselines, MCCB domains r = 0.69-0.90. Baseline 2 and follow-up SB composites correlated r = 0.65-0.80 and MCCB domains r = 0.62-0.87. MCCB tasks' practice effects (Glass' ∆ = 0.02-0.46) exceeded SB's (Glass' ∆ = 0.02-0.34). While the batteries' total scores correlated strongly (r = 0.79-0.82), apparently equivalent cognitive domains on each battery (e.g. psychomotor-attention) correlated r = 0.22-0.60, indicating substantial differences between some supposed counterparts.CONCLUSIONS: Clinical trials using either battery would benefit from initial practice sessions to ameliorate practice effects but the SB may be more suitable to measure change in the absence of repeated baselines. The MCCB domains' better correlations with social skills performance suggest that it may have an advantage for measuring cognition in relation to functional outcome.",
keywords = "CogState Schizophrenia Battery, Cognition, MATRICS MCCB, Schizophrenia, UPSA-B",
author = "Jane Lees and Eve Applegate and Richard Emsley and Shon Lewis and Michalopoulou, {Panayiota G.} and Tracy Collier and Cristina Lopez-Lopez and S Kapur and Gahan Pandina and Richard Drake",
year = "2015",
month = "5",
day = "29",
doi = "10.1007/s00213-015-3960-8",
language = "English",
volume = "232",
pages = "3873--3882",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Nature",
number = "21-22",

}

RIS

TY - JOUR

T1 - Calibration and cross-validation of MCCB and CogState in schizophrenia

AU - Lees, Jane

AU - Applegate, Eve

AU - Emsley, Richard

AU - Lewis, Shon

AU - Michalopoulou, Panayiota G.

AU - Collier, Tracy

AU - Lopez-Lopez, Cristina

AU - Kapur, S

AU - Pandina, Gahan

AU - Drake, Richard

PY - 2015/5/29

Y1 - 2015/5/29

N2 - RATIONALE: Cognitive impairment associated with schizophrenia is a key predictor of functional outcomes. The FDA-accepted MATRICS Consensus Cognitive Battery (MCCB) is held to be the gold standard measure but there are concerns about its ease of administration, reliance on language causing problems with translation and possible practice effects. The CogState Schizophrenia Battery (SB) is suggested as a non-language-based alternative but there is no substantial, independent comparison.OBJECTIVES: The objective of this study was to assess the reliability and validity of these two assessment batteries.METHODS: One hundred forty-three participants with DSM-IV schizophrenia and schizoaffective disorder were recruited into three similar studies. Each study administered MCCB and SB tests on consecutive days (baseline 1 and 2) and follow-up 3-4 weeks later.RESULTS: Batteries' test-retest reliability was similar: SB composites correlated r = 0.66-0.78 between baselines, MCCB domains r = 0.69-0.90. Baseline 2 and follow-up SB composites correlated r = 0.65-0.80 and MCCB domains r = 0.62-0.87. MCCB tasks' practice effects (Glass' ∆ = 0.02-0.46) exceeded SB's (Glass' ∆ = 0.02-0.34). While the batteries' total scores correlated strongly (r = 0.79-0.82), apparently equivalent cognitive domains on each battery (e.g. psychomotor-attention) correlated r = 0.22-0.60, indicating substantial differences between some supposed counterparts.CONCLUSIONS: Clinical trials using either battery would benefit from initial practice sessions to ameliorate practice effects but the SB may be more suitable to measure change in the absence of repeated baselines. The MCCB domains' better correlations with social skills performance suggest that it may have an advantage for measuring cognition in relation to functional outcome.

AB - RATIONALE: Cognitive impairment associated with schizophrenia is a key predictor of functional outcomes. The FDA-accepted MATRICS Consensus Cognitive Battery (MCCB) is held to be the gold standard measure but there are concerns about its ease of administration, reliance on language causing problems with translation and possible practice effects. The CogState Schizophrenia Battery (SB) is suggested as a non-language-based alternative but there is no substantial, independent comparison.OBJECTIVES: The objective of this study was to assess the reliability and validity of these two assessment batteries.METHODS: One hundred forty-three participants with DSM-IV schizophrenia and schizoaffective disorder were recruited into three similar studies. Each study administered MCCB and SB tests on consecutive days (baseline 1 and 2) and follow-up 3-4 weeks later.RESULTS: Batteries' test-retest reliability was similar: SB composites correlated r = 0.66-0.78 between baselines, MCCB domains r = 0.69-0.90. Baseline 2 and follow-up SB composites correlated r = 0.65-0.80 and MCCB domains r = 0.62-0.87. MCCB tasks' practice effects (Glass' ∆ = 0.02-0.46) exceeded SB's (Glass' ∆ = 0.02-0.34). While the batteries' total scores correlated strongly (r = 0.79-0.82), apparently equivalent cognitive domains on each battery (e.g. psychomotor-attention) correlated r = 0.22-0.60, indicating substantial differences between some supposed counterparts.CONCLUSIONS: Clinical trials using either battery would benefit from initial practice sessions to ameliorate practice effects but the SB may be more suitable to measure change in the absence of repeated baselines. The MCCB domains' better correlations with social skills performance suggest that it may have an advantage for measuring cognition in relation to functional outcome.

KW - CogState Schizophrenia Battery

KW - Cognition

KW - MATRICS MCCB

KW - Schizophrenia

KW - UPSA-B

U2 - 10.1007/s00213-015-3960-8

DO - 10.1007/s00213-015-3960-8

M3 - Article

C2 - 26018529

VL - 232

SP - 3873

EP - 3882

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 21-22

ER -